Results 111 to 120 of about 24,552 (280)

Trade Wars, International Supply Chains, and Business Associations: Historical Evidence from Norway and Portugal

open access: yesJournal of Management Studies, EarlyView.
Abstract This article examines the 1921–1923 trade war between Norway and Portugal as a historical case for exploring business responses to deglobalization and trade disruption. Focusing on the international supply chains (ISCs) of port wine and salted and dried cod, it investigates how business actors contributed to the recoupling of ISCs after a ...
Rolv Petter Amdam   +3 more
wiley   +1 more source

Development and Release of the Munich UICC Staging Tool (MUST): Advancing UICC Staging in Real‐World Data With Insights From Pancreatic and Stomach Cancer

open access: yesInternational Journal of Cancer, Volume 159, Issue 3, Page 757-767, 1 August 2026.
Accurate cancer staging is essential for cancer research and treatment evaluation. However, real‐world data often include incomplete or inconsistent UICC staging classifications. The presented Munich UICC Staging Tool (MUST) automates UICC stage derivation from TNM classifications and tumor characteristics, incorporating novel real‐world data rules to ...
Brigitte Kühnel   +18 more
wiley   +1 more source

A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors

open access: yesPlatelets, 2020
Phillip LR. Nicolson   +5 more
doaj   +1 more source

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis

open access: yesTherapeutic Advances in Neurological Disorders
Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ...
Laura Airas   +8 more
doaj   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1632-1649, July 2026.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan   +10 more
wiley   +1 more source

Progress and Challenges in Phylogenomics and Genomics of Lophotrochozoa/Spiralia

open access: yesZoologica Scripta, Volume 55, Issue 4, Page 521-544, July 2026.
ABSTRACT Lophotrochozoa is one of the three major bilaterian groups comprising more than half of the bilaterian phyla. Lophotrochozoa includes among others Mollusca, Annelida, Platyhelminthes and Rotifera. Despite representing such a large proportion of animal diversity, they are historically understudied and genomic resources have been scarce. However,
Torsten H. Struck
wiley   +1 more source

Reviewer #2 (Public Review): Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states

open access: gold, 2023
David Yin-wei Lin   +5 more
openalex   +1 more source

Mechanisms of resistance to BTK inhibitors independent of BTK and PLCG2 mutations

open access: yes
Bruton's tyrosine kinase inhibitors (BTKis) have transformed chronic lymphocytic leukemia (CLL) therapy, yet resistance remains a major challenge. While often driven by BTK or PLCG2 mutations, some resistant cases lack these alterations, and mechanisms are unclear.
openaire   +1 more source

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

open access: yesChemMedChem, Volume 21, Issue 11, 15 June 2026.
Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy